Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese Participants With Atopic Dermatitis

Inclusion Criteria

• •Diagnosis of moderate to severe atopic dermatitis (AD) at the time of enrollment.
• •Chinese adolescents (≥12 to \<18 years of age with body weight of ≥40 kg) or adults (≥18 years of age) at the time of enrollment.
• •Participants eligible for initiation of Upadacitinib treatment for AD, including any required screening tests indicated per China Label.
• •The decision to prescribe Upadacitinib is made prior to and independently of study participation.